Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 extension study of itacitinib for participants previously enrolled in Incyte-sponsored itacitinib studies
MOH_2023-03-12_012415Phase 2Not yet recruiting
- Sponsor
- Incyte
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of itacitinib in myelofibrosis (MF), Bronchiolitis Obliterans Syndrome (BOS) and graft-versus-host disease (GVHD), sponsored by Incyte. Primary endpoint: Safety evaluation. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
itacitinib
03
Conditions
myelofibrosis (MF)Bronchiolitis Obliterans Syndrome (BOS)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on MOH_2023-03-12_012415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-12_012415.